A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Clinical trial NCT07155174 · RECRUITING
Trial details
- NCT number
- NCT07155174
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-25
- Primary completion
- 2029-04-01
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.